An advantage of ENaC inhibition is that it has the potential to circumvent CFTR function and CFTR mutation class (19, 20) and could thus be applicable to all patients with CF, notably those possessing rare mutations who do not currently have access to approved CFTR modulator therapy (21). Here, CFTR is linked to cystic fibrosis.